ABSTRACT
Diet is a significant modifiable risk factor for type 2 diabetes (T2D), and its effect on disease risk is under partial genetic control. Identification of specific gene-diet interactions (GDIs) influencing risk biomarkers such as glycated hemoglobin (HbA1c) is a critical step towards developing precision nutrition for T2D prevention, but progress has been slow due to limitations in sample size and accuracy of dietary exposure measurement. We leveraged the large sample size of the UK Biobank (UKB) cohort and a diverse group of dietary exposures, including 30 individual dietary traits and 8 empirical dietary patterns, to conduct genome-wide interaction studies in ∼340,000 European-ancestry participants to identify novel GDIs influencing HbA1c. We identified five variant-dietary trait pairs reaching genome-wide significance (p < 5×10−8): two involved dietary patterns (meat pattern with rs147678157 and a fruit &vegetable-based pattern with rs3010439) and three involved individual dietary traits (bread consumption with rs62218803, dried fruit consumption with rs140270534, and milk type [dairy vs. other] with 4:131148078_TAGAA_T). All of these were affected minimally by adjustment for geographical and lifestyle-related confounders, and four of the five variants lacked any genetic main effect that would have allowed their detection in a traditional genome-wide association study for HbA1c. Notably, multiple loci near transient receptor potential subfamily M genes (TRPM2 and TRPM3) were identified as interacting with carbohydrate-containing food groups. Some of these interactions showed nominal replication in non-European ancestry UKB subsets, as well as association using alternative measures of glycemia (fasting glucose and follow-up HbA1c measurements). Our results highlight relevant GDIs influencing HbA1c for future investigation, while reinforcing known challenges in detecting and replicating GDIs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KEW was supported by National Institutes of Health grant [R01 HL145025]. JBC was supported by American Diabetes Association 1-19-PDF-028.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was conducted under a Not Human Subjects Research determination (NHSR-4298 at the Broad Institute of MIT and Harvard).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UK Biobank data can be accessed at https://www.ukbiobank.ac.uk/.
